Protagonist Therapeutics
PTGX
140 hedge funds and large institutions have $1.19B invested in Protagonist Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 47 reducing their positions, and 29 closing their positions.
259% more call options, than puts
Call options by funds: $52.9M | Put options by funds: $14.7M
15% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 47
1% more ownership
Funds ownership: 103.59% → 104.59% (+1%)
6% less funds holding
Funds holding: 149 → 140 (-9)
29% less capital invested
Capital invested by funds: $1.67B → $1.19B (-$486M)
31% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 29
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$61.8M |
| 2 |
Morgan Stanley
New York
|
+$34.6M |
| 3 |
CAC
Cowen and Company
New York
|
+$20.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.3M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$15.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$63.6M |
| 2 |
DM
Deerfield Management
New York
|
-$40.1M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$22.1M |
| 4 |
SC
Samlyn Capital
New York
|
-$15.4M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$14.8M |
PTGX Hedge Fund Activity: Q1 2022 in Review
140 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2022, worth a combined $1.19B — down 29% from $1.67B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PTGX and 20 opened new positions — a net loss of 9 holders — while 47 trimmed existing stakes and 54 added.
The largest buyer was RTW Investments, adding an estimated $61.8M. The largest seller was EcoR1 Capital, cutting an estimated $63.6M.
- 140 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2022, down from 149 in Q4 2021.
- Funds reported $1.19B of Protagonist Therapeutics stock for Q1 2022, down 29% quarter-over-quarter.
- 20 funds opened new Protagonist Therapeutics positions in Q1 2022 and 29 closed out, a net change of -9 holders.
- The largest Protagonist Therapeutics buyer in Q1 2022 was RTW Investments, an estimated $61.8M added.
- The largest Protagonist Therapeutics seller in Q1 2022 was EcoR1 Capital, an estimated $63.6M sold.
Based on aggregated 13F filings for Q1 2022.